Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 695
Gene Symbol: BTK
BTK
0.400 Biomarker disease BEFREE The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib is inducing durable responses in chronic lymphocytic leukemia (CLL) patients with refractory/relapsed disease or with TP53 defect, with BTK and phospholipase C gamma 2 (PLCG2) mutations representing the predominant mechanisms conferring secondary ibrutinib resistance. 31180577 2020
Entrez Id: 695
Gene Symbol: BTK
BTK
0.400 Biomarker disease BEFREE Bruton's tyrosine kinase inhibitor ibrutinib has become a leading therapy against chronic lymphoid leukemia. 31171644 2020
Entrez Id: 695
Gene Symbol: BTK
BTK
0.400 Biomarker disease BEFREE These 4 agents include the Bruton tyrosine kinase inhibitor ibrutinib, the B-cell leukemia/lymphoma-2 inhibitor venetoclax, and the phosphatidylinositol-3 kinase inhibitors idelalisib and duvelisib. 31764124 2020
Entrez Id: 695
Gene Symbol: BTK
BTK
0.400 Biomarker disease BEFREE The Bruton tyrosine kinase (BTK) inhibitor ibrutinib is increasingly used in the treatment of chronic lymphocytic leukemia (CLL). 31699465 2020
Entrez Id: 695
Gene Symbol: BTK
BTK
0.400 Biomarker disease BEFREE The development of drugs able to target BTK, PI3k-delta and BCL2 has dramatically improved chronic lymphocytic leukaemia (CLL) therapies. 31821686 2020
Entrez Id: 695
Gene Symbol: BTK
BTK
0.400 GeneticVariation disease BEFREE Elderly chronic lymphocytic leukaemia (CLL) patients treated outside of trials have notably greater toxicity with the Bruton's tyrosine kinase inhibitor ibrutinib compared to younger patients. 31682002 2020
Entrez Id: 695
Gene Symbol: BTK
BTK
0.400 AlteredExpression disease BEFREE Based on our previous finding that a humanized monoclonal antibody against ROR1 increases the activity of Ibrutinib against CLL, which is currently undergoing evaluation in clinical trials for the treatment of B-cell lymphoid malignancies, we then provided evidence that treatment with HSP90i (17-DMAG) enhances anti-CLL activity of Ibrutinib in vitro and in vivo, by down-modulating ROR1. iTRAQ-based quantitative proteomic analysis of other HSP90 oncogenic clients in addition to ROR1, followed by GO/KEGG enrichment analysis, showed that Bruton's Tyrosine Kinase (BTK), B-lymphoid Tyrosine Kinase (BLK), Lymphocyte-specific Protein Tyrosine Kinase (LCK), or LCK/YES-Related Novel Protein Tyrosine Kinase (LYN), as HSP90 clients, were significantly involved in 11 biological processes and 6 signaling pathways. 31726100 2020
Entrez Id: 695
Gene Symbol: BTK
BTK
0.400 AlteredExpression disease BEFREE Chronic activation of the Bruton's tyrosine kinase (BTK)-mediated B-cell receptor (BCR) signaling is a hallmark of many B-cell lymphoid malignancies, including chronic lymphocytic leukemia (CLL) and diffuse large B-cell lymphoma (DLBCL). 31801949 2019
Entrez Id: 695
Gene Symbol: BTK
BTK
0.400 Biomarker disease BEFREE Ibrutinib, a Bruton's tyrosine kinase inhibitor has reformed the treatment of various B-cell malignancies including chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom's macroglobulinemia. 30045682 2019
Entrez Id: 695
Gene Symbol: BTK
BTK
0.400 Biomarker disease BEFREE The Bruton tyrosine kinase (BTK) inhibitor ibrutinib has substantially improved therapeutic options for chronic lymphocytic leukemia (CLL). 30692684 2019
Entrez Id: 695
Gene Symbol: BTK
BTK
0.400 AlteredExpression disease BEFREE The results showed that compound <b>11g</b> displayed the best inhibitory activity on BTK with an inhibition rate of 82.76% at 100 nM and excellent anti-proliferation activity on three B-cell leukemia lines (IC<sub>50</sub> = 3.66 μM, 6.98 μM, and 5.39 μM against HL60, Raji and Ramos, respectively). 30881616 2019
Entrez Id: 695
Gene Symbol: BTK
BTK
0.400 GeneticVariation disease BEFREE Ibrutinib, an oral inhibitor of the Bruton's tyrosine kinase (BTK) has proved to be remarkably efficient against treatment naïve (TN), heavily pre-treated and high-risk chronic lymphocytic leukaemia (CLL), with limited adverse events. 31076570 2019
Entrez Id: 695
Gene Symbol: BTK
BTK
0.400 Biomarker disease BEFREE We investigated a next-generation phosphoinositide-3-kinase-δ inhibitor (PI3K-δi), umbralisib, plus a Bruton tyrosine kinase inhibitor (BTKi), ibrutinib, in relapsed or refractory chronic lymphocytic leukaemia and mantle cell lymphoma. 30558987 2019
Entrez Id: 695
Gene Symbol: BTK
BTK
0.400 Biomarker disease BEFREE Ibrutinib is a small molecule drug that targets Bruton's tyrosine kinase in B-cell malignancies and is highly efficient at killing mantle cell lymphoma and chronic lymphocytic leukemia. 30663221 2019
Entrez Id: 695
Gene Symbol: BTK
BTK
0.400 AlteredExpression disease BEFREE The expression levels of BTK and p-BTK on CD5<sup>+</sup>B lymphocytes in AIHA/ES patients were higher than those in HCs and CLL patients. 31392938 2019
Entrez Id: 695
Gene Symbol: BTK
BTK
0.400 Biomarker disease BEFREE Expert opinion: Treatment options for CLL have increased significantly with the introduction of the BTK inhibitors, PI3K inhibitors, BCL2 inhibitors, and novel anti-CD20 monoclonal antibodies. 30686074 2019
Entrez Id: 695
Gene Symbol: BTK
BTK
0.400 Biomarker disease BEFREE In 2013, ibrutinib was approved by the FDA as the first-in-class BTK inhibitors for the treatment of mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL), and now it is also undergoing clinical evaluation for other indications in either single or combined therapy. 30888232 2019
Entrez Id: 695
Gene Symbol: BTK
BTK
0.400 Biomarker disease BEFREE We evaluated the safety, efficacy, pharmacokinetics, pharmacodynamics and predictive biomarkers of tirabrutinib, a second-generation, enhanced-selectivity Bruton's tyrosine kinase inhibitor in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-cell NHL) and chronic lymphocytic leukemia (CLL). 30815927 2019
Entrez Id: 695
Gene Symbol: BTK
BTK
0.400 GeneticVariation disease BEFREE Mutational analyses performed following acquired ibrutinib resistance have suggested that chronic lymphocytic leukemia (CLL) progression on ibrutinib is linked to mutations in Bruton tyrosine kinase (<i>BTK</i>) and/or phospholipase Cγ2 (<i>PLCG2</i>) genes. 31243043 2019
Entrez Id: 695
Gene Symbol: BTK
BTK
0.400 Biomarker disease BEFREE While the Bruton's tyrosine kinase inhibitor (BTKi) ibrutinib has revolutionized the treatment of chronic lymphocytic leukemia (CLL), current limitations include off-target toxicities and the development of resistance. 31028669 2019
Entrez Id: 695
Gene Symbol: BTK
BTK
0.400 Biomarker disease BEFREE The functional relevance of BTK for lymphoid malignancies is strongly supported by the observation that resistance to therapy in CLL patients treated with BTK inhibitors such as ibrutinib is often associated with mutations in genes coding for BTK or Phospholipase-C gamma (PLCɣ). 30700840 2019
Entrez Id: 695
Gene Symbol: BTK
BTK
0.400 Biomarker disease BEFREE Our results demonstrate that CC-292 is a specific BTK inhibitor with promising performance in combination with bendamustine in CLL. 30468254 2019
Entrez Id: 695
Gene Symbol: BTK
BTK
0.400 Biomarker disease BEFREE Inhibition of Bruton tyrosine kinase (BTK) is a breakthrough therapy for certain B cell lymphomas and B cell chronic lymphatic leukemia. 31217352 2019
Entrez Id: 695
Gene Symbol: BTK
BTK
0.400 AlteredExpression disease BEFREE In primary chronic lymphocytic leukemia (CLL) lymphocytes, pharmacological interference with mitochondrial ATP synthesis or glucose metabolism affects BTK activity. 31363127 2019
Entrez Id: 695
Gene Symbol: BTK
BTK
0.400 Biomarker disease BEFREE Ibrutinib, a BTK inhibitor, has demonstrated marked efficacy and tolerability in treatment-naïve, relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and mantle cell lymphoma (MCL). 31638169 2019